$78.8 Billion is the total value of Versant Venture Management, LLC's 5 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLVS | Sell | Clovis Oncology, Inc. | $35,803,718,000 | -40.8% | 407,416 | -50.0% | 45.41% | -14.6% |
| KYTH | Exit | Kythera Biopharmaceuticals, Inc. | $0 | – | -70,376 | -100.0% | -3.10% | – |
| INGN | Exit | Inogen, Inc. | $0 | – | -155,284 | -100.0% | -4.37% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-07-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 26 | Q2 2024 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 21 | Q2 2024 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 18 | Q2 2024 | 21.0% |
| Aligos Therapeutics, Inc. | 15 | Q2 2024 | 15.7% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Passage Bio, Inc. | 14 | Q2 2024 | 21.8% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-13 |
| 13F-HR | 2024-08-07 |
| 13F-HR | 2024-05-03 |
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.